Addressing stability challenges of mRNA-LNP therapies by Kerstin Pohl | 0 CommentsIn a recent webinar, available on demand, Jingtao Zhang (PhD), Scientific Director, and Daniel Turner, Scientist at Catalent® Pharma Solutions, presented their approaches to addressing stability challenges of mRNA-based products.
A new approach for comprehensive AAV evaluation including full and empty analysis by Kerstin Pohl | 0 CommentsCertain next-gen vaccines and gene therapy applications rely on the usage of adeno-associated viruses (AAV) as a delivery vehicle. To ensure the safety and efficacy of viral vector drugs, multiple critical quality attributes (CQAs) need to be well characterized.
Addressing stability challenges of mRNA-LNP therapies by Kerstin Pohl | Biopharma, BioPhase 8800 system, BlogsIn a recent webinar, available on demand, Jingtao Zhang (PhD), Scientific Director, and Daniel Turner, Scientist at Catalent® Pharma Solutions, presented their approaches to addressing stability challenges of mRNA-based products.
A new approach for comprehensive AAV evaluation including full and empty analysis by Kerstin Pohl | Biopharma, BioPhase 8800 system, BlogsCertain next-gen vaccines and gene therapy applications rely on the usage of adeno-associated viruses (AAV) as a delivery vehicle. To ensure the safety and efficacy of viral vector drugs, multiple critical quality attributes (CQAs) need to be well characterized.